72 results
6-K
EX-99.1
ASLN
ASLAN Pharmaceuticals Ltd
22 Apr 24
Aslan Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of Eblasakimab In Dupilumab-experienced Atopic Dermatitis Patients
8:29am
of the rescue medication for the purpose of efficacy analyses. Missing data were analysed using Last Observation Carried Forward imputation.
4.Least squares
424B5
ASLN
ASLAN Pharmaceuticals Ltd
12 Apr 24
Prospectus supplement for primary offering
8:15am
this offering to be used for any particular purpose, our management will have broad discretion as to the application of the net proceeds from … purpose. Pending application of the net proceeds as described above, we may initially invest the net proceeds in short-term, investment-grade
6-K
EX-99.1
ASLN
ASLAN Pharmaceuticals Ltd
12 Apr 24
Amendment No. 2 to the Open Market Sale Agreementsm
8:10am
correctly sets forth the understanding between the Company and the Agent, please so indicate in the space provided below for that purpose, whereupon
S-8
ASLN
ASLAN Pharmaceuticals Ltd
12 Apr 24
Registration of securities for employees
6:37am
(the “Registrant”) is filing this Registration Statement on Form S-8 for the purpose of registering an additional 17,597,059 ordinary shares (an equivalent
F-3
7ux1s
25 Mar 24
Shelf registration (foreign)
4:46pm
424B5
ro706dv6jd
14 Mar 24
Prospectus supplement for primary offering
6:24am
6-K
EX-4.1
k9jdusgf1u5hinrho
13 Mar 24
Aslan Pharmaceuticals Announces $5 Million Registered Direct Offering
7:27am
6-K
EX-10.1
mrpibdtdjxwp2vt fdab
13 Mar 24
Aslan Pharmaceuticals Announces $5 Million Registered Direct Offering
7:27am
6-K
EX-99.1
pbgw heyx
24 Jan 24
Current report (foreign)
7:52am
6-K
EX-99.2
n9hy2o
22 Dec 23
Current report (foreign)
4:24pm
F-6EF
kdowovxcrgqtkc oy8
26 Apr 23
Automatic registration for ADRs (foreign)
5:26pm
F-6EF
EX-99
rfvssfbywz3i7 l2j7t
26 Apr 23
Automatic registration for ADRs (foreign)
5:26pm
F-6EF
EX-99
w6uward1636ak0re iwe
26 Apr 23
Automatic registration for ADRs (foreign)
5:26pm
6-K
EX-99.2
ol20v1rrxs7gzv5ze
21 Dec 22
Current report (foreign)
6:03am
6-K
EX-99.1
57o1x1gw
13 Sep 22
Amendment No. 1 to the Open Market Sale Agreementsm
4:31pm
424B5
99ztjwz436oqwn48txvr
13 Sep 22
Prospectus supplement for primary offering
4:05pm